<DOC>
	<DOC>NCT01327235</DOC>
	<brief_summary>The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.</brief_summary>
	<brief_title>Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites</brief_title>
	<detailed_description />
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Pleural Effusion, Malignant</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histological or cytological diagnosis of thoracic or abdominal tumor At least medium amount of malignant pleural effusion or ascites ECOG Performance Status 02 Life expectancy â‰¥ 2 months Adequate hematologic, cardiac, renal, and hepatic function No major surgery within 4 weeks prior to this study Written informed consent Patients with central nervous system (CNS) metastases Evidence of bleeding diathesis, serious infection Evidence of myocardial infarction, unstable angina or cardiac insufficiency Presence of serious COPD and/or respiratory failure Allergic to study drug Pregnant or lactating women Participation in other clinical trials within 30 days prior to this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>